Existing user? Login

Bortezomib for multiple myeloma approved in Wales

Patients in Wales with multiple myeloma may now receive treatment with bortezomib (Velcade) through the NHS, the Welsh Minister for Health and Social Services has announced following recommendations from the All Wales Medicines Strategy Group.

The drug may be used for patients who have experienced disease progression despite already receiving two other therapies. Treatment must only be initiated and administered under the supervision of an appropriately qualified and experienced doctor.

The minister has also endorsed the AWMSG’s recommendation that the use of pegvisomant (Somavert) for the treatment of acromegaly should not be supported in Wales.

Citation: Electronicjuice URI: 10020530

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Electronicjuice, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

вимакс 60 капсул купить в украине отзывы